Arcturus

$26.66 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Arcturus

Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines and vaccines company. The Company’s technologies include LUNAR lipid-mediated delivery, STARR mRNA Technology and mRNA drug substance along with drug product manufacturing. Its pipeline of ribonucleic acid (RNA) therapeutic candidates include programs to treat ornithine transcarbamylase (OTC) deficiency, cystic fibrosis, glycogen storage disease type three, hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for severe acute respiratory syndrome coronavirus two (SARS-CoV-2). Its RNA therapeutics platforms have applications in types of nucleic acid medicines, including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, deoxyribonucleic acid (DNA) and gene editing therapeutics. The Company is focused on liver and respiratory diseases.

Stock Analysis

last close $27.21
1-mo return -42.2%
3-mo return -40.4%
avg daily vol. 452.02T
52-week high 89.18
52-week low 24.87
market cap. $883M
forward pe -
annual div. -
roe -74%
ltg forecast -
dividend yield -
annual rev. $29M
inst own. 70.1%
baraka

Subscribe now for daily local and international financial news

Subscribe